Investigating the Effects of Aerobic and Resistance Training in Vivo on Skeletal Muscle Metabolism in Vitro in Primary Human Muscle Cells (MoTrMyo)
NCT ID: NCT04334343
Last Updated: 2025-03-13
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
NA
Total Enrollment
400 participants
Study Classification
INTERVENTIONAL
Study Start Date
2020-11-01
Study Completion Date
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The goal of the study is to examine the ability of resistance or aerobic exercise training to "imprint" skeletal muscle cells in a manner which confers long-term changes in this tissue which in-turn contribute to improved metabolic health and functional capacity through epigenetic regulation of novel exercise response genes. This study will also provide primary human skeletal muscle cells to the Molecular Transducers of Physical Activity Consortium (MoTrPAC) (NCT03960827) repository for future use.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Aging and the Mitochondrial Response to Exercise Training, Measured by Noninvasive 31P Magnetic Resonance Spectroscopy
NCT04799171
Physical Activity
COMPLETED
NA
Trial of the Effects of Remote Preconditioning on the Tissue Metabolism During Exercise and Ischemia
NCT00791206
Ischemia
UNKNOWN
PHASE2
Training Induced Muscle Exosome Release
NCT04500769
Metabolism
COMPLETED
NA
Myotonic Dystrophy Type 1 Aerobic Exercise Study
NCT04187482
Myotonic Dystrophy 1
Muscular Dystrophies
COMPLETED
NA
Evaluating Changes in Skeletal Muscle Proteins Following Resistance Exercise and Single-Leg Disuse
NCT06350591
Healthy
Skeletal Muscle Atrophy
Skeletal Muscle Hypertrophy
COMPLETED
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Physical Activity
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
OTHER
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Athletic group
Group Type
ACTIVE_COMPARATOR
Additional Muscle Biopsy Collection
Intervention Type
OTHER
Subjects will be asked if an additional biopsy from an existing incision can be obtained (i.e. additional needle insertion). For each biopsy required in the main MoTrPAC study (NCT03960827), a small needle will be used to inject some numbing medication (similar to what a dentist uses) in your thigh. A small incision (about 1/4 inch) will be made and a special needle will be used to collect 1 or 2 muscle samples (about the size of a pea).
Sedentary exercise group
Group Type
ACTIVE_COMPARATOR
Additional Muscle Biopsy Collection
Intervention Type
OTHER
Subjects will be asked if an additional biopsy from an existing incision can be obtained (i.e. additional needle insertion). For each biopsy required in the main MoTrPAC study (NCT03960827), a small needle will be used to inject some numbing medication (similar to what a dentist uses) in your thigh. A small incision (about 1/4 inch) will be made and a special needle will be used to collect 1 or 2 muscle samples (about the size of a pea).
Sedentary no-exercise group
Group Type
ACTIVE_COMPARATOR
Additional Muscle Biopsy Collection
Intervention Type
OTHER
Subjects will be asked if an additional biopsy from an existing incision can be obtained (i.e. additional needle insertion). For each biopsy required in the main MoTrPAC study (NCT03960827), a small needle will be used to inject some numbing medication (similar to what a dentist uses) in your thigh. A small incision (about 1/4 inch) will be made and a special needle will be used to collect 1 or 2 muscle samples (about the size of a pea).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Additional Muscle Biopsy Collection
Subjects will be asked if an additional biopsy from an existing incision can be obtained (i.e. additional needle insertion). For each biopsy required in the main MoTrPAC study (NCT03960827), a small needle will be used to inject some numbing medication (similar to what a dentist uses) in your thigh. A small incision (about 1/4 inch) will be made and a special needle will be used to collect 1 or 2 muscle samples (about the size of a pea).
Intervention Type
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Willingness to provide informed consent to participate in the MoTrPAC Study
-Willingness to undergo an extra needle insertion for the extra muscle tissue collection during the MoTrPAC muscle biopsy
* Must be able to read and speak English well enough to provide informed consent and understand instructions
* Aged ≥18 y
* Body Mass Index (BMI) \>19 to \<35 kg/m2
* Sedentary defined as self-reporting no more than 1 day per week, lasting no more than 60 minutes, of regular (structured) EE \[e.g., brisk walking, jogging, running, cycling, elliptical, or swimming activity that results in feelings of increased heart rate, rapid breathing, and/or sweating\] or RE (resulting in muscular fatigue) in the past year
* Persons bicycling as a mode of transportation to and from work \>1 day/week etc. are not considered sedentary
* Leisure walkers are included unless they meet the heart rate, breathing, and sweating criteria noted above
* Willingness to provide informed consent to participate in the MoTrPAC Study
-Willingness to undergo an extra needle insertion for the extra muscle tissue collection during the MoTrPAC muscle biopsy
* Must be able to read and speak English well enough to provide informed consent and understand instructions
* Aged ≥18 y
* BMI \>19 to \<35 kg/m2
* Comparator Participants
* Highly Active Endurance Exercise (HAEE): defined as \>240 minutes/week of ET for \>1 year; this can include running, walking (brisk, power), cycling, elliptical, etc. which (at a minimum) results in increased heart rate, rapid breathing and sweating
* Must include cycling at least 2 days/week
* Highly Active Resistance Exercise (HARE): defined as RT of ≥3 upper and ≥3 lower body muscle groups ≥2 times/week for \>1 year; using a prescription sufficient to increase strength and muscle mass
* Potential participants are informed that use of performance enhancing drugs in the last 6 months is exclusionary
-Willingness to undergo an extra needle insertion for the extra muscle tissue collection during the MoTrPAC muscle biopsy
* Must be able to read and speak English well enough to provide informed consent and understand instructions
* Aged ≥18 y
* Body Mass Index (BMI) \>19 to \<35 kg/m2
* Sedentary defined as self-reporting no more than 1 day per week, lasting no more than 60 minutes, of regular (structured) EE \[e.g., brisk walking, jogging, running, cycling, elliptical, or swimming activity that results in feelings of increased heart rate, rapid breathing, and/or sweating\] or RE (resulting in muscular fatigue) in the past year
* Persons bicycling as a mode of transportation to and from work \>1 day/week etc. are not considered sedentary
* Leisure walkers are included unless they meet the heart rate, breathing, and sweating criteria noted above
* Willingness to provide informed consent to participate in the MoTrPAC Study
-Willingness to undergo an extra needle insertion for the extra muscle tissue collection during the MoTrPAC muscle biopsy
* Must be able to read and speak English well enough to provide informed consent and understand instructions
* Aged ≥18 y
* BMI \>19 to \<35 kg/m2
* Comparator Participants
* Highly Active Endurance Exercise (HAEE): defined as \>240 minutes/week of ET for \>1 year; this can include running, walking (brisk, power), cycling, elliptical, etc. which (at a minimum) results in increased heart rate, rapid breathing and sweating
* Must include cycling at least 2 days/week
* Highly Active Resistance Exercise (HARE): defined as RT of ≥3 upper and ≥3 lower body muscle groups ≥2 times/week for \>1 year; using a prescription sufficient to increase strength and muscle mass
* Potential participants are informed that use of performance enhancing drugs in the last 6 months is exclusionary
Exclusion Criteria
* Diabetes (self-report and screening tests)
* Treatment with any hypoglycemic agents (self-report) or A1c \>6.4 (screening test; may reassess once if 6.5-6.7)
* Fasting glucose \>125 (screening test; may reassess once)
* Use of hypoglycemic drugs (e.g., metformin) for non-diabetic reasons (self-report)
* Abnormal bleeding or coagulopathy (self-report)
◦History of a bleeding disorder or clotting abnormality
* Thyroid disease (screening test)
* Thyroid Stimulating Hormone (TSH) value outside of the normal range for the laboratory
* Individuals with hypothyroidism may be referred to their primary care provider (PCP) for evaluation and retested; any medication change must be stable for ≥3 months prior to retesting
* Individuals with hyperthyroidism are excluded, including those with normal TSH on pharmacologic treatment
* Pulmonary (self-report)
◦Clinical diagnosis of Chronic Obstructive Pulmonary Disease (COPD)
* Metabolic bone disease (self-report)
* History of non-traumatic fracture from a standing height or less
* Current pharmacologic treatment for low bone mass or osteoporosis, other than calcium, vitamin D, or estrogen
* Estrogens, progestins (self-report)
◦Supplemental, replacement or therapeutic use of estrogens or progestins within the last 6 months, other than birth control or to control menopausal symptoms
* Pregnancy (screening test) and pregnancy-related conditions (self-report)
* Pregnant - pregnancy test performed on day of DXA scan in women of child-bearing potential
* Post-partum during the last 12 months
* Lactating during the last 12 months
* Planning to become pregnant during the participation period
* Elevated blood pressure readings (screening test)
* Aged \<60 years: Resting Systolic Blood Pressure (SBP) ≥140 mmHg or Resting Diastolic Blood Pressure (DBP) ≥90 mmHg
* Aged ≥60 years: Resting SBP ≥150 mmHg or Resting DBP ≥90 mmHg
* Reassessment of BP during screening will be allowed to ensure rested values are obtained
* Cardiovascular (self-report, screening test, and clinician judgement)
* Congestive heart failure, coronary artery disease, significant valvular disease, congenital heart disease, serious arrhythmia, stroke, or symptomatic peripheral artery disease (self-report, screening test)
* Specific criteria used to determine whether a volunteer can undergo the screening Cardiopulmonary Exercise Test (CPET) follow the American Heart Association (AHA) Criteria \[54\]
* Inability to complete the CPET
* Abnormal blood lipid profile (screening test)
* Fasting triglycerides \>500 mg/dL
* Low-density lipoprotein cholesterol (LDL-C) \>190mg/dL
* Cancer (self-report)
* History of cancer treatment (other than non-melanoma skin cancer) and not "cancer-free" for at least 2 years
* Anti-hormonal therapy (e.g., for breast or prostate cancer) within the last 6 months
* Chronic infection (self-report)
* Infections requiring chronic antibiotic or anti-viral treatment
* Human Immunodeficiency Virus
* Individuals successfully treated for hepatitis C and virologically negative for at least 6 months are not excluded
* Liver enzyme tests (Alanine transaminase, Aspartate transaminase) (screening test)
◦\>2 times the laboratory upper limit of normal
* Reassessment during screening may be allowed under some conditions (e.g., recent use of acetaminophen)
* Individuals may be referred to their PCP for evaluation; any medication change must be stable for ≥3 months prior to retesting
* Chronic renal insufficiency (screening test)
* Estimated glomerular filtration rate \<60 mL/min/1.73 m2 from serum creatinine (mg/dL) by the Chronic Kidney Disease Epidemiology Collaboration equation
* Reassessment may be allowed under some conditions (e.g., questionable hydration status or other acute renal insult)
* Hematocrit (screening test)
* Hematocrit \>3 points outside of the local normal laboratory ranges for women and men
* Reassessment may be allowed under certain conditions
* Individuals may be referred to their PCP for evaluation; any medication change must be stable for ≥3 months prior to retesting
* Individuals with known thalassemia trait may be included (despite having \>3 points outside of the local normal laboratory ranges), upon approval from their PCP or a hematologist
* Blood donation (self-report)
* Whole blood donation in the last 3 months or plans for blood donation during the entire protocol period
* Platelet or plasma donation in the last week or plans for platelet or plasma donation during the entire protocol period
* Autoimmune disorders (self-report)
◦Individuals receiving any active treatment (including monoclonal antibodies) within the last 6 months
* Alcohol consumption (self-report)
* More than 7 drinks per week for women
* More than 14 drinks per week for men
* History of binge drinking (≥5 drinks for males or ≥4 drinks for females in a 2-hour period more than once per month)
* Tobacco (self-report)
◦Self-reported use ≥3 days/week of tobacco or e-cigarette/e-nicotine products
* Marijuana (self-report)
◦Self-reported use ≥3 days/week in any form
* Shift workers (self-report)
* Night shift work in the last 6 months
* Planning night shift work during the study period
* Cognitive status (screening)
◦Unable to give consent to participate in and safely complete the protocol, as based on the judgement of the local investigator
* Psychiatric illness (self-report and screening test)
* Hospitalization for any psychiatric condition within one year (self-report)
* Center for Epidemiological Studies-Depression Scale (CESD) score ≥16 \[55\] (screening test)
* Weight change (self-report)
* Weight change (intentional or not) over the last 6 months of \>5% of body weight
* Plan to lose or gain weight during the study
* Lidocaine or other local anesthetic (self-report)
◦Known allergy to lidocaine or other local anesthetic
* Other (clinician judgement)
* Any other cardiovascular, pulmonary, orthopedic, neurologic, psychiatric or other conditions that, in the opinion of the local clinician, would preclude participation and successful completion of the protocol
* Any other illnesses that, in the opinion of the local clinician, would negatively impact or mitigate participation in and completion of the protocol
EXCLUSIONS FOR MEDICATION USE
* Use of any new drug in the last 3 months
* Dose change for any drug in the last within 3 months
* Cardiovascular
* Beta blockers and centrally acting anti-hypertensive drugs (clonidine, guanfacine and alpha-methyl-dopa)
* Anticoagulants (coumadin or Direct Oral Anticoagulants)
* Antiarrhythmic drugs: amiodarone, dronaderone, profafenone, disopyrimide, quinidine
* Antiplatelet drugs (other than aspirin ≥100 mg/day): dipyridamole, clopidogrel, ticagrelor
* Lipid-lowering medications
* Participants who volunteer to stop lipid-lowering medications for the duration of the study are allowed; inclusion requires lipid-lowering medication to be stopped for 3 months and participant re-evaluated for LDL-C eligibility
* Psychiatric drugs
* Chronic use of medium or long-acting sedatives and hypnotics (short-acting non-benzodiazepine sedative-hypnotics are allowed)
* All benzodiazepines
* Tricyclic antidepressants at a dose ≥75 mg total dose per day
* Two or more drugs for depression
* Mood stabilizers
* Antiepileptic drugs
* Stimulants, Attention-Deficit/Hyperactivity Disorder (ADHD) drugs
* Muscle relaxants
◦Methacarbamol; cyclobenzaprine; tizanidine; baclofen
* Pulmonary, inflammation
* Chronic oral steroids
* Burst/taper oral steroids more than once in the last 12 months
* B2-agonists
* allowed if on stable dose at least 3 months
* Genitourinary
* Finasteride or dutasteride
* Daily phosphodiesterase type 5 inhibitor use
* Hormonal
* Testosterone, dehydroepiandrosterone, anabolic steroids
* Anti-estrogens, anti-androgens
* Growth hormone, insulin like growth factor-I, growth hormone releasing hormone
* Any drugs used to treat diabetes mellitus or to lower blood glucose
* Metformin for any indication
* Any drugs used specifically to induce weight loss
* Any drugs used specifically to induce muscle growth/hypertrophy or augment exercise-induced muscle hypertrophy
* Pain/inflammation
* Narcotics and narcotic receptor agonists
* Regular use of non-steroidal anti-inflammatory drugs (NSAIDs) or acetaminophen ≥3 days per week
* Other
* Anti-malarials
* Low-potency topical steroids if ≥10% of surface area using rule of 9s
* Any other medications that, in the opinion of local clinicians, would negatively impact or mitigate full participation and completion
* Treatment with any hypoglycemic agents (self-report) or A1c \>6.4 (screening test; may reassess once if 6.5-6.7)
* Fasting glucose \>125 (screening test; may reassess once)
* Use of hypoglycemic drugs (e.g., metformin) for non-diabetic reasons (self-report)
* Abnormal bleeding or coagulopathy (self-report)
◦History of a bleeding disorder or clotting abnormality
* Thyroid disease (screening test)
* Thyroid Stimulating Hormone (TSH) value outside of the normal range for the laboratory
* Individuals with hypothyroidism may be referred to their primary care provider (PCP) for evaluation and retested; any medication change must be stable for ≥3 months prior to retesting
* Individuals with hyperthyroidism are excluded, including those with normal TSH on pharmacologic treatment
* Pulmonary (self-report)
◦Clinical diagnosis of Chronic Obstructive Pulmonary Disease (COPD)
* Metabolic bone disease (self-report)
* History of non-traumatic fracture from a standing height or less
* Current pharmacologic treatment for low bone mass or osteoporosis, other than calcium, vitamin D, or estrogen
* Estrogens, progestins (self-report)
◦Supplemental, replacement or therapeutic use of estrogens or progestins within the last 6 months, other than birth control or to control menopausal symptoms
* Pregnancy (screening test) and pregnancy-related conditions (self-report)
* Pregnant - pregnancy test performed on day of DXA scan in women of child-bearing potential
* Post-partum during the last 12 months
* Lactating during the last 12 months
* Planning to become pregnant during the participation period
* Elevated blood pressure readings (screening test)
* Aged \<60 years: Resting Systolic Blood Pressure (SBP) ≥140 mmHg or Resting Diastolic Blood Pressure (DBP) ≥90 mmHg
* Aged ≥60 years: Resting SBP ≥150 mmHg or Resting DBP ≥90 mmHg
* Reassessment of BP during screening will be allowed to ensure rested values are obtained
* Cardiovascular (self-report, screening test, and clinician judgement)
* Congestive heart failure, coronary artery disease, significant valvular disease, congenital heart disease, serious arrhythmia, stroke, or symptomatic peripheral artery disease (self-report, screening test)
* Specific criteria used to determine whether a volunteer can undergo the screening Cardiopulmonary Exercise Test (CPET) follow the American Heart Association (AHA) Criteria \[54\]
* Inability to complete the CPET
* Abnormal blood lipid profile (screening test)
* Fasting triglycerides \>500 mg/dL
* Low-density lipoprotein cholesterol (LDL-C) \>190mg/dL
* Cancer (self-report)
* History of cancer treatment (other than non-melanoma skin cancer) and not "cancer-free" for at least 2 years
* Anti-hormonal therapy (e.g., for breast or prostate cancer) within the last 6 months
* Chronic infection (self-report)
* Infections requiring chronic antibiotic or anti-viral treatment
* Human Immunodeficiency Virus
* Individuals successfully treated for hepatitis C and virologically negative for at least 6 months are not excluded
* Liver enzyme tests (Alanine transaminase, Aspartate transaminase) (screening test)
◦\>2 times the laboratory upper limit of normal
* Reassessment during screening may be allowed under some conditions (e.g., recent use of acetaminophen)
* Individuals may be referred to their PCP for evaluation; any medication change must be stable for ≥3 months prior to retesting
* Chronic renal insufficiency (screening test)
* Estimated glomerular filtration rate \<60 mL/min/1.73 m2 from serum creatinine (mg/dL) by the Chronic Kidney Disease Epidemiology Collaboration equation
* Reassessment may be allowed under some conditions (e.g., questionable hydration status or other acute renal insult)
* Hematocrit (screening test)
* Hematocrit \>3 points outside of the local normal laboratory ranges for women and men
* Reassessment may be allowed under certain conditions
* Individuals may be referred to their PCP for evaluation; any medication change must be stable for ≥3 months prior to retesting
* Individuals with known thalassemia trait may be included (despite having \>3 points outside of the local normal laboratory ranges), upon approval from their PCP or a hematologist
* Blood donation (self-report)
* Whole blood donation in the last 3 months or plans for blood donation during the entire protocol period
* Platelet or plasma donation in the last week or plans for platelet or plasma donation during the entire protocol period
* Autoimmune disorders (self-report)
◦Individuals receiving any active treatment (including monoclonal antibodies) within the last 6 months
* Alcohol consumption (self-report)
* More than 7 drinks per week for women
* More than 14 drinks per week for men
* History of binge drinking (≥5 drinks for males or ≥4 drinks for females in a 2-hour period more than once per month)
* Tobacco (self-report)
◦Self-reported use ≥3 days/week of tobacco or e-cigarette/e-nicotine products
* Marijuana (self-report)
◦Self-reported use ≥3 days/week in any form
* Shift workers (self-report)
* Night shift work in the last 6 months
* Planning night shift work during the study period
* Cognitive status (screening)
◦Unable to give consent to participate in and safely complete the protocol, as based on the judgement of the local investigator
* Psychiatric illness (self-report and screening test)
* Hospitalization for any psychiatric condition within one year (self-report)
* Center for Epidemiological Studies-Depression Scale (CESD) score ≥16 \[55\] (screening test)
* Weight change (self-report)
* Weight change (intentional or not) over the last 6 months of \>5% of body weight
* Plan to lose or gain weight during the study
* Lidocaine or other local anesthetic (self-report)
◦Known allergy to lidocaine or other local anesthetic
* Other (clinician judgement)
* Any other cardiovascular, pulmonary, orthopedic, neurologic, psychiatric or other conditions that, in the opinion of the local clinician, would preclude participation and successful completion of the protocol
* Any other illnesses that, in the opinion of the local clinician, would negatively impact or mitigate participation in and completion of the protocol
EXCLUSIONS FOR MEDICATION USE
* Use of any new drug in the last 3 months
* Dose change for any drug in the last within 3 months
* Cardiovascular
* Beta blockers and centrally acting anti-hypertensive drugs (clonidine, guanfacine and alpha-methyl-dopa)
* Anticoagulants (coumadin or Direct Oral Anticoagulants)
* Antiarrhythmic drugs: amiodarone, dronaderone, profafenone, disopyrimide, quinidine
* Antiplatelet drugs (other than aspirin ≥100 mg/day): dipyridamole, clopidogrel, ticagrelor
* Lipid-lowering medications
* Participants who volunteer to stop lipid-lowering medications for the duration of the study are allowed; inclusion requires lipid-lowering medication to be stopped for 3 months and participant re-evaluated for LDL-C eligibility
* Psychiatric drugs
* Chronic use of medium or long-acting sedatives and hypnotics (short-acting non-benzodiazepine sedative-hypnotics are allowed)
* All benzodiazepines
* Tricyclic antidepressants at a dose ≥75 mg total dose per day
* Two or more drugs for depression
* Mood stabilizers
* Antiepileptic drugs
* Stimulants, Attention-Deficit/Hyperactivity Disorder (ADHD) drugs
* Muscle relaxants
◦Methacarbamol; cyclobenzaprine; tizanidine; baclofen
* Pulmonary, inflammation
* Chronic oral steroids
* Burst/taper oral steroids more than once in the last 12 months
* B2-agonists
* allowed if on stable dose at least 3 months
* Genitourinary
* Finasteride or dutasteride
* Daily phosphodiesterase type 5 inhibitor use
* Hormonal
* Testosterone, dehydroepiandrosterone, anabolic steroids
* Anti-estrogens, anti-androgens
* Growth hormone, insulin like growth factor-I, growth hormone releasing hormone
* Any drugs used to treat diabetes mellitus or to lower blood glucose
* Metformin for any indication
* Any drugs used specifically to induce weight loss
* Any drugs used specifically to induce muscle growth/hypertrophy or augment exercise-induced muscle hypertrophy
* Pain/inflammation
* Narcotics and narcotic receptor agonists
* Regular use of non-steroidal anti-inflammatory drugs (NSAIDs) or acetaminophen ≥3 days per week
* Other
* Anti-malarials
* Low-potency topical steroids if ≥10% of surface area using rule of 9s
* Any other medications that, in the opinion of local clinicians, would negatively impact or mitigate full participation and completion
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Wake Forest University
OTHER
Sponsor Role
collaborator
AdventHealth Translational Research Institute
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lauren Sparks, PhD
Role: PRINCIPAL_INVESTIGATOR
Study Principal Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
AdventHealth Translational Research Institute
Orlando, Florida, United States
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
United States
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Myers J, Prakash M, Froelicher V, Do D, Partington S, Atwood JE. Exercise capacity and mortality among men referred for exercise testing. N Engl J Med. 2002 Mar 14;346(11):793-801. doi: 10.1056/NEJMoa011858.
Reference Type
BACKGROUND
Kokkinos P, Myers J, Kokkinos JP, Pittaras A, Narayan P, Manolis A, Karasik P, Greenberg M, Papademetriou V, Singh S. Exercise capacity and mortality in black and white men. Circulation. 2008 Feb 5;117(5):614-22. doi: 10.1161/CIRCULATIONAHA.107.734764. Epub 2008 Jan 22.
Reference Type
BACKGROUND
Egan B, Zierath JR. Exercise metabolism and the molecular regulation of skeletal muscle adaptation. Cell Metab. 2013 Feb 5;17(2):162-84. doi: 10.1016/j.cmet.2012.12.012.
Reference Type
BACKGROUND
Reaven GM, Chen YD. Role of abnormal free fatty acid metabolism in the development of non-insulin-dependent diabetes mellitus. Am J Med. 1988 Nov 28;85(5A):106-12. doi: 10.1016/0002-9343(88)90402-0. No abstract available.
Reference Type
BACKGROUND
Snijders T, Nederveen JP, McKay BR, Joanisse S, Verdijk LB, van Loon LJ, Parise G. Satellite cells in human skeletal muscle plasticity. Front Physiol. 2015 Oct 21;6:283. doi: 10.3389/fphys.2015.00283. eCollection 2015.
Reference Type
BACKGROUND
Ceccarelli G, Benedetti L, Arcari ML, Carubbi C, Galli D. Muscle Stem Cell and Physical Activity: What Point is the Debate at? Open Med (Wars). 2017 Jul 24;12:144-156. doi: 10.1515/med-2017-0022. eCollection 2017.
Reference Type
BACKGROUND
Murach KA, Fry CS, Kirby TJ, Jackson JR, Lee JD, White SH, Dupont-Versteegden EE, McCarthy JJ, Peterson CA. Starring or Supporting Role? Satellite Cells and Skeletal Muscle Fiber Size Regulation. Physiology (Bethesda). 2018 Jan 1;33(1):26-38. doi: 10.1152/physiol.00019.2017.
Reference Type
BACKGROUND
Boyle KE, Patinkin ZW, Shapiro ALB, Bader C, Vanderlinden L, Kechris K, Janssen RC, Ford RJ, Smith BK, Steinberg GR, Davidson EJ, Yang IV, Dabelea D, Friedman JE. Maternal obesity alters fatty acid oxidation, AMPK activity, and associated DNA methylation in mesenchymal stem cells from human infants. Mol Metab. 2017 Nov;6(11):1503-1516. doi: 10.1016/j.molmet.2017.08.012. Epub 2017 Sep 1.
Reference Type
BACKGROUND
Stephens NA, Sparks LM. Resistance to the beneficial effects of exercise in type 2 diabetes: are some individuals programmed to fail? J Clin Endocrinol Metab. 2015 Jan;100(1):43-52. doi: 10.1210/jc.2014-2545.
Reference Type
BACKGROUND
Ukropcova B, McNeil M, Sereda O, de Jonge L, Xie H, Bray GA, Smith SR. Dynamic changes in fat oxidation in human primary myocytes mirror metabolic characteristics of the donor. J Clin Invest. 2005 Jul;115(7):1934-41. doi: 10.1172/JCI24332.
Reference Type
BACKGROUND
Aas V, Bakke SS, Feng YZ, Kase ET, Jensen J, Bajpeyi S, Thoresen GH, Rustan AC. Are cultured human myotubes far from home? Cell Tissue Res. 2013 Dec;354(3):671-82. doi: 10.1007/s00441-013-1655-1. Epub 2013 Jun 8.
Reference Type
BACKGROUND
Berggren JR, Tanner CJ, Houmard JA. Primary cell cultures in the study of human muscle metabolism. Exerc Sport Sci Rev. 2007 Apr;35(2):56-61. doi: 10.1249/JES.0b013e31803eae63.
Reference Type
BACKGROUND
Gaster M, Kristensen SR, Beck-Nielsen H, Schroder HD. A cellular model system of differentiated human myotubes. APMIS. 2001 Nov;109(11):735-44. doi: 10.1034/j.1600-0463.2001.d01-140.x.
Reference Type
BACKGROUND
Ciaraldi TP, Abrams L, Nikoulina S, Mudaliar S, Henry RR. Glucose transport in cultured human skeletal muscle cells. Regulation by insulin and glucose in nondiabetic and non-insulin-dependent diabetes mellitus subjects. J Clin Invest. 1995 Dec;96(6):2820-7. doi: 10.1172/JCI118352.
Reference Type
BACKGROUND
Gaster M. Reduced lipid oxidation in myotubes established from obese and type 2 diabetic subjects. Biochem Biophys Res Commun. 2009 May 15;382(4):766-70. doi: 10.1016/j.bbrc.2009.03.102. Epub 2009 Mar 24.
Reference Type
BACKGROUND
Lund J, Rustan AC, Lovsletten NG, Mudry JM, Langleite TM, Feng YZ, Stensrud C, Brubak MG, Drevon CA, Birkeland KI, Kolnes KJ, Johansen EI, Tangen DS, Stadheim HK, Gulseth HL, Krook A, Kase ET, Jensen J, Thoresen GH. Exercise in vivo marks human myotubes in vitro: Training-induced increase in lipid metabolism. PLoS One. 2017 Apr 12;12(4):e0175441. doi: 10.1371/journal.pone.0175441. eCollection 2017.
Reference Type
BACKGROUND
Bourlier V, Saint-Laurent C, Louche K, Badin PM, Thalamas C, de Glisezinski I, Langin D, Sengenes C, Moro C. Enhanced glucose metabolism is preserved in cultured primary myotubes from obese donors in response to exercise training. J Clin Endocrinol Metab. 2013 Sep;98(9):3739-47. doi: 10.1210/jc.2013-1727. Epub 2013 Jul 24.
Reference Type
BACKGROUND
Consitt LA, Bell JA, Koves TR, Muoio DM, Hulver MW, Haynie KR, Dohm GL, Houmard JA. Peroxisome proliferator-activated receptor-gamma coactivator-1alpha overexpression increases lipid oxidation in myocytes from extremely obese individuals. Diabetes. 2010 Jun;59(6):1407-15. doi: 10.2337/db09-1704. Epub 2010 Mar 3.
Reference Type
BACKGROUND
Hulver MW, Berggren JR, Carper MJ, Miyazaki M, Ntambi JM, Hoffman EP, Thyfault JP, Stevens R, Dohm GL, Houmard JA, Muoio DM. Elevated stearoyl-CoA desaturase-1 expression in skeletal muscle contributes to abnormal fatty acid partitioning in obese humans. Cell Metab. 2005 Oct;2(4):251-61. doi: 10.1016/j.cmet.2005.09.002.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1436585
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Strength Training Effects on Musculoskeletal Health
NCT04810975
ACTIVE_NOT_RECRUITING
NA
Inspiratory Muscle Training Using the O2 Trainer
NCT07005622
COMPLETED
NA
Augmenting a Post-Stroke Wellness Program With Respiratory Muscle Training
NCT05819333
ACTIVE_NOT_RECRUITING
NA
Respiratory Muscles and Inspiratory Muscle Training
NCT02243527
COMPLETED
NA
Chronic Obstructive Pulmonary Disorder and Acute Exercise
NCT02780219
COMPLETED
NA
Lung Volume Recruitment Combined With Expiratory Muscle Strength Training in ALS
NCT03202017
COMPLETED
NA
A Randomized, Controlled Trial of Inspiratory Muscle Training (IMT)in the ICU and CCU
NCT02003053
COMPLETED
NA
Eccentric Resistance Training With Blood Flow Restriction on Muscle Function
NCT04977804
WITHDRAWN
NA
Blood Flow Reserve: Effects After Training With Heavy Inspiratory Exercises
NCT05632614
ACTIVE_NOT_RECRUITING
NA
Effect of Inspiratory Muscle Training on Exercise Performance and Quality of Life in Patients With Chronic Obstructive Pulmonary Disease
NCT02257463
COMPLETED
NA
Study of the Effects of Temperature on Metabolism in Human Muscle
NCT00001753
COMPLETED
PHASE1
Inspiratory Muscle Training in Amateur CrossFit® Athletes
NCT06807957
RECRUITING
NA
A Study to Evaluate Breathing Muscle Training in Cardiac Rehab
NCT04984473
RECRUITING
NA
Regulation of Satellite Cells and Myogenesis in Response to Eccentric Resistance Exercise in Hypoxia
NCT07341165
COMPLETED
NA
Skeletal Muscle Mitochondria in Ageing
NCT06539078
RECRUITING
Effect of Inspiratory Muscle Training on Physiological Function and Clinical Outcomes After Lung Transplant
NCT04783155
RECRUITING
NA
Inspiratory Muscle Training in Amateur Athletes
NCT06611969
ACTIVE_NOT_RECRUITING
NA
Abdominal Adiposity and Muscle Mitochondrial Functions
NCT00446745
COMPLETED
Effects of Inspiratory Muscle Fatigue and Warm-up on Respiratory Variables, Handgrip Strength, and Walking Capacity in Sedentary Older Adults
NCT06895304
NOT_YET_RECRUITING
NA
Respiratory Muscle Training in Patients With Spinal Muscular Atrophy (SMA).
NCT05632666
UNKNOWN
NA
Low-Load Blood Flow Restriction on Patients With Multiple Sclerosis
NCT05177952
COMPLETED
NA
Strength Training Augmenting Rehabilitation
NCT05097092
UNKNOWN
NA
The Effect of Blood Flow Restriction (Bfr) Exercise on Acute Systemic Myokine Levels in Healthy Trained Men
NCT05573321
UNKNOWN
NA
Exercise Training and Respiratory Muscle Training in Individuals With Metabolic Syndrome(METS)
NCT05413434
COMPLETED
NA
Respiratory Muscle Training (RMT) in ALS
NCT04224961
COMPLETED
NA